NCT06907849
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
Enrolling by Invitation
PHASE2Ages 60+InterventionalDiagnosticUniversity of Tennessee Graduate School of MedicineInvestigator-initiated
~40 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:124I-evuzamitide
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Detection of cardiac amyloidosis using 124I-evuzamitide PET/CT imaging
Measured over From enrollment to the end of study is 8 days.
Conditions
Where it's being run
1 sites across 1 statesTennessee1
Study leadership
- Emily B. Martin, PhD · PRINCIPAL_INVESTIGATOR · University of Tennessee Graduate School of Medicine
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Must be ≥ 60 years of age.
Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
Must have a Congo red positive ligamentum flavum or tenosynovial specimen analysis after laminectomy or carpal tunnel release surgery that is visually categorized as either "extensive" amyloid load or "mild/moderate" amyloid load by an experienced reviewer.
Those with mild/moderate amyloid load in the connective tissue who also have a history of at least one other orthopedic clinical manifestation, including, but not limited to, carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture, and shoulder/hip/knee arthroplasty.
Females must be non-pregnant and non-lactating.
Exclusion
Subjects on dialysis.
Subjects with a confirmed diagnosis of systemic amyloidosis, other than musculoskeletal tissue.
Inability or unwillingness to comply with the study requirements.
Subjects taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.
Inability to lie still for \~40 minutes on the PET/CT scanner.
History of iodine (potassium iodide) allergy.
Other reason that would make the subject inappropriate for entry into this study.
What this trial measures
- Detection of cardiac amyloidosis using 124I-evuzamitide PET/CT imagingFrom enrollment to the end of study is 8 days.
Cardiac PET/CT images will be classified as either positive or negative for 124I-evuzamitide uptake based on visual interpretation.